What the Study Found (In Plain English)
Published in Journal of endocrinological investigation (2016), this meta-analysis evaluating human clinical outcomes investigated: To assess the efficacy, safety and impact on β-cell function of DPP-4 inhibitors plus metformin in T2DM patients and their difference between Asians and Caucasians. Key clinical takeaway: DPP-4 inhibitors and metformin therapy was effective and safe for T2DM patients. The glucose-lowering efficacy of DPP-4 inhibitors was same in Asian and Caucasian patients, although the effect on HOMA-β was inferior in Asian patients.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Journal of endocrinological investigation, 2016-09-15; Meta-Analysis; Rigor 86/100): DPP-4 inhibitors and metformin therapy was effective and safe for T2DM patients. The glucose-lowering efficacy of DPP-4 inhibitors was same in Asian and Caucasian patients, although the effect on HOMA-β was inferior in Asian patients.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Meta-Analysis). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.